Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828673 | 0.82 | MEN1 (0.47) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL23719293 | 0.82 | SMN1; SMN2 (0.39) | PIM1AURKACDK2GSK3BKDR | |
| SCHEMBL23719252 | 0.79 | TP53 (0.52) | CDK2GSK3BSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23719268 | 0.79 | ADORA3 (0.51) | PIM1AURKACDK2GSK3BKDR | |
| SCHEMBL23719163 | 0.77 | IDH2 (0.49) | KDRIDH2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23719151 | 0.73 | KMT2A (0.49) | KDRSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL23719200 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2AMAPTTAAR1 | |
| SCHEMBL4600722 | 0.71 | AURKA (1.00) | PIM1AURKACDK2GSK3BSMN1; SMN2 | |
| SCHEMBL3777152 | 0.70 | ECE1 (0.46) | CDK2GSK3BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL22828374 | 0.68 | STING1 (0.55) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PIM1 2978/4885AURKA 3471/4885CDK2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.